INTERPRETATION A history of dysphagia and/or aspiration pneumonia are the factors that most increase the likelihood of systemic adverse events after BoNT-A.
Botulinum neurotoxin A (BoNT-A) has now been a standard treatment for hypertonia (spasticity and/or dystonia) in cerebral palsy (CP) for more than 20 years. During that time, an evidence base has been established to support its use in ambulant [1] [2] [3] [4] and non-ambulant [5] [6] [7] children with CP. During the same period there have been concerns raised about the safety of BoNT-A, particularly in children with severe CP. In 2008 the U.S. Food and Drug Administration reviewed the literature and the Adverse Event Reporting System database, and identified nine deaths and other serious adverse events associated with the treatment. 8 They advised that clinicians be alert to and educate patients and caregivers about potential adverse events due to distant spread of botulinum neurotoxin, highlighting symptoms similar to botulism such as dysphagia, generalized weakness, and lower respiratory tract illnesses. 9 In this context, it is imperative that families and clinicians have sufficient information about BoNT-A to make informed decisions that include understanding potential benefits and the likelihood and severity of any adverse events. 10 However, understanding the potential risks of BoNT-A is complex. Adverse events have a temporal but not necessarily causative relationship with BoNT-A, and children with severe CP often have comorbidities (e.g. dysphagia) that increase their risk of adverse health consequences whether or not they are treated with BoNT-A. Additionally, different types of adverse events do not have equal importance for families and clinicians. Studies that report total adverse event rates may overstate risk by grouping mild adverse events (e.g. bruising) with those more significant (e.g. aspiration pneumonia).
Several studies have been published that support decisionmaking in this area. Total adverse events after BoNT-A have been reported to occur in 3.3% to 56% of injection episodes, [11] [12] [13] [14] [15] reflecting different study designs. Adverse events with symptoms suggesting systemic spread are less common, 16 estimated to occur in 1% to 2.2% of injection episodes. 11, 15, 17 Previous studies have suggested that increased BoNT-A dose 17 and more severe gross motor disability (as classified by the Gross Motor Function Classification System [GMFCS]) 13, 17 increase the likelihood of adverse events after BoNT-A. However, increasing GMFCS level is associated with increased rates of other impairments including some (e.g. pseudobulbar palsy) that plausibly might contribute to the likelihood of adverse events. 18, 19 Other factors (including those related to the patient and the treatment) may also be important. More research is needed to enable clinicians and families to identify patient and injection factors that increase the likelihood of systemic adverse events and to adjust clinical management accordingly.
We have previously reported rates of various adverse events for 591 children with CP after 2219 BoNT-A injection episodes 20 and identified that children in GMFCS levels IV and V have increased likelihood of systemic adverse events. The likelihood of systemic adverse events for this group may be better explained by other factors related to either the patient or injection. The present study was undertaken to better understand the factors that increase likelihood of systemic adverse events for children with CP after BoNT-A injection.
METHOD
The study took place in an outpatient BoNT-A clinic of a rehabilitation department in a tertiary children's hospital based in Sydney, Australia.
The setting has been described previously. 11, 20 Children who attend the clinic typically undergo assessment for injection of BoNT-A in the same half-day time period. Assessment is undertaken by a multidisciplinary team consisting of a rehabilitation paediatrician, physiotherapist, and occupational therapist; goals for BoNT-A and target muscles are agreed at this stage. Injections then typically proceed using EMLA (AstraZeneca Pty Ltd, Sodertalje, Sweden) local anaesthetic cream, nitrous oxide conscious sedation, and ultrasound guidance for needle location. A minority of children have additional sedation (usually midazolam), or a general anaesthetic. Follow-up is scheduled with one of the clinicians involved approximately 30 days after BoNT-A treatment by either face-to-face or telephone consultation. At this time, effectiveness of BoNT-A and the occurrence of any adverse events after treatment are discussed. During the study time-frame, information relating to the child's CP, comorbidities, health status in the month before injection, BoNT-A injections, and adverse events was collected in a standardized way into a written pro forma with prompts for pertinent information including the adverse events reported here. Data were entered into a purpose-built Microsoft Access database.
All children with a diagnosis of CP who received BoNT-A injections between July 2010 and June 2014 were included in the study. Systemic adverse events were defined as any report of generalized weakness, dysphagia (or worsening dysphagia in those known to have dysphagia already), lower respiratory tract illnesses, and death, consistent with the descriptions provided by the U.S. Food and Drug Administration. Other adverse events that could suggest local or regional spread (e.g. incontinence) or where the biological mechanism was unclear (e.g. seizures) were not included. Further details about systemic adverse events were gathered when available, through reference to the child's electronic medical records. Adverse events were classified as either mild (if they had no/ minimal impact on health and well-being and required no treatment), requiring community medical treatment (if they were reviewed or treated in an outpatient or general practice setting), or serious (if they required attendance at an emergency department or admission to hospital to receive treatment).
Eight preinjection variables were studied based on availability, previous studies, and clinical experience. Six variables related to patient factors (age, GMFCS level, history of dysphagia [defined as requiring food modification and/ or feeding tube], gastrostomy, history of aspiration pneumonia, and a recent history of illness) and two variables to treatment factors (BoNT-A dose [units/kg]; use of sedation). Botox (Allergan plc, Dublin, Ireland) was used in all cases; at a standard dilution of 100 units in 2ml 0.9% saline. Standard practice was for Botox total dose to not exceed 16 units/kg (up to a maximum of 400 units). Children typically received BoNT-A every 4 to 6 months as clinically appropriate.
Associations between preinjection variables and systemic adverse events were examined using logistic regression with generalized estimating equations methods with binomial distribution of the outcome and exchangeable correlation structure. 21 This method was chosen because of the longitudinal nature of data collection; some children received several injections during the study time-frame. The nature of the variables, in that there were both categorical and continuous variables, did not allow other methods such as Poisson regression to be used. GMFCS was treated as a categorical variable with GMFCS level I as the reference category. Sedation types were treated as categorical variables with no sedation as the reference category. Univariable analyses were conducted first. A multivariable model was constructed including all variables; this was felt not to result in overfitting. 22 A backward elimination approach was then used using sequential multivariable models. After each model, one variable was eliminated if it was found to not contribute significantly to the outcome (p>0.05) and by comparison of the quasi-likelihood under independence model criterion for the two models. This process was repeated until only variables with a p-value lower than 0.05 remained. Other multivariable models using only variables with significance level of p-value lower than 0.05 in the univariable analysis were constructed in the same manner. Statistical analyses were performed using SPSS version 22 (IBM Corp., Armonk, NY, USA).
What this paper adds
• Systemic adverse events occur in 3.6% of botulinum neurotoxin A (BoNT-A) injection episodes.
• Dysphagia and/or aspiration pneumonia are associated with increased likelihood of systemic adverse events.
• Multivariable models showed no evidence of association between Gross Motor Function Classification System and systemic adverse events.
• Multivariable models showed no evidence of association between BoNT-A dose and systemic adverse events.
The study received ethical approval from the Sydney Children's Hospitals Network Human Research Ethics Committee (LNR/14/SCHN/330).
RESULTS
During the study time-frame, 591 children (328 [55.5%] male, 263 [44.5%] female) underwent a total of 2219 BoNT-A injection episodes (Table I ). The mean dose of BoNT-A injected was 9.6 units/kg (standard deviation 4.6 units/kg). A small number of children received higher doses than typically used, with 61 (2.7%) receiving more than 18.0 units/kg and 13 (0.6%) receiving more than 20.0 units/kg (maximum 22.9 units/kg). Patients ranged between 10 months and 20 years of age (median 9y 1mo) at time of injection. A total of 83 adverse events suggesting systemic spread of BoNT-A were reported in 77 (3.6%) injection episodes. Generalized weakness was reported in 16 cases (0.7% of injection episodes); dysphagia (or worsening of pre-existing dysphagia) in 33 cases (1.5% of injection episodes); lower respiratory tract illnesses in 33 cases (1.5% of injection episodes); and one death.
Most adverse events were either mild (36 injection episodes) or required community medical treatment (23 injection episodes) (Table II) . More severe sequelae from systemic adverse events resulting in hospitalization occurred in 18 (0.7%) injection episodes; there was one (expected) death in a child who was receiving palliative care (Table III) . One further child was admitted with a prolonged decreased level of consciousness 30 days after BoNT-A injection in the context of previous similar episodes without preceding BoNT-A. The cause of these episodes was eventually determined to have been induced by ingestion of prescribed medication. Seventeen further children died during the study time-frame but at times more remote from BoNT-A injections (median 212d, interquartile range 110-473d).
Univariable analysis
Univariable analysis suggested that, compared with children in GMFCS level I, children in GMFCS level IV (odds ratio [OR] 4.13) and GMFCS level V (OR 7.96), and children with a previous history of dysphagia (OR 4.52), gastrostomy (OR 3.06), and/or aspiration pneumonia (OR 4.55) had increased likelihood of systemic adverse events after BoNT-A injection (Table IV) . Increasing BoNT-A dose (units/kg; OR 1.07) also increased the likelihood of systemic adverse events (Table IV) . There was no statistical evidence of a relationship with the other patient factors (age, history of a recent illness) or treatment factors (sedation type).
Multivariable analysis
In the final multivariable model (Table V) , a history of dysphagia (OR 3.42) and a history of aspiration pneumonia (OR 2.31) remained significantly associated with increased likelihood of systemic adverse events. Other models constructed using only variables identified to have statistically significant associations with systemic adverse events resulted in the same multivariable model variables with similar coefficients and statistical significance to the final model.
DISCUSSION
Improving understanding about the potential adverse events related to BoNT-A treatment in children with CP is highly important to clinicians and families. In this study we aimed to build on the findings of our previous study. 20 We examined factors that increase the likelihood of the most concerning adverse events, those that suggest systemic spread of the toxin to distant parts of the body, with the intention of improving understanding of which children with CP have the greatest likelihood of experiencing systemic adverse events. We found evidence of systemic adverse events in 3.6% of BoNT-A injection episodes. Most adverse events were mild, but in several cases children were hospitalized with symptoms to which BoNT-A may have contributed. Multivariable logistic regression using generalized estimating equations suggested that a previous history of dysphagia and/or aspiration pneumonia were the most important factors that increase likelihood of systemic adverse events for children in our population.
Our results are broadly consistent with major published literature concerning CP and BoNT-A adverse events. The rate of systemic adverse events we report here and the results of our univariable analyses are consistent with other studies that have examined adverse events after BoNT-A injection. 11, 13, 17 These studies have suggested that GMFCS is associated with increased rates of adverse events 13 and unplanned hospital admissions after BoNT-A. 17 Increasing dose (units/kg) has also been suggested to be associated with increased emergency department presentations. 17 Gastrostomy has also been suggested to be associated with more severe adverse events in a study of children in GMFCS levels IV and V. 12 We acknowledge the considerable overlap between those children with dysphagia and those with a gastrostomy.
However, our multivariable analyses suggest that the most important factors that increase the likelihood of systemic adverse events after BoNT-A injection in moderate doses are a history of dysphagia and of previous aspiration pneumonia. Additionally, these analyses suggest that, when considering these patient and injection variables, no statistically significant association between GMFCS level and systemic adverse events remains. This suggests that the relationship between severity of CP as measured through the GMFCS and systemic adverse events found in univariate analyses within this and previous research is due to the association between increased severity of CP and other comorbidities such as dysphagia and aspiration pneumonia. This finding is relevant to clinical practice. We feel that, using GMFCS alone as a risk factor, clinicians may overestimate the risk of systemic adverse events in children who function at more severe GMFCS levels who do not have dysphagia and/or a history of aspiration pneumonia and may underestimate risk in children with dysphagia and/or aspiration pneumonia who function at a less severe GMFCS level. Limitations of our study include that we were not able to measure all factors that might increase the likelihood of systemic adverse events. Other factors of interest would include site of injection and the presence of other comorbidities (e.g. epilepsy has been associated with adverse events in one study). 13 Similarly, in other populations, other variables may also be found to predict systemic adverse events. We acknowledge that many of the variables we tested are correlated to some extent; it is well recognized that children with more severe CP are more likely to have related comorbidities. Most injections were also performed within moderate dosing guidelines, consistent with local practice; whether higher dosing regimens increase likelihood systemic adverse events is unclear. Our study, like others, is also vulnerable to reporting bias, being dependent on parent/carer report. We chose to limit our definition of systemic adverse events to be consistent with the descriptions provided by the U.S. Food and Drug Administration. It is possible that other adverse events were caused by distant spread of injection toxin. Incontinence has been reported as due to systemic toxin spread in some studies, 17 whereas other studies 11 support incontinence being caused by more localized spread. The main limitation, consistent with previous literature, remains the challenge of determining a causative role for BoNT-A in the systemic adverse events examined. The presence of pathological organisms in some of the cases we present suggest that other mechanisms have at least contributed to some of the illnesses described. The diagnosis of aspiration pneumonia can also be imprecise in the absence of a clear precipitating episode. Other studies have suggested that a requirement for food modifications and/or presence of nasogastric or gastrostomy feeding increase risk of hospitalization because of respiratory illness; 23 respiratory failure because of aspiration and/or pneumonia has been identified as the leading cause of death in CP. 24 As severe adverse events are not common, very large randomized controlled trials would be required to better understand any causative role of BoNT-A in these respiratory events. The mechanisms underlying systemic spread of BoNT-A to distant body parts remain unclear. Various mechanisms have been proposed, including neuroaxonal and haematogenous migration, both which have been supported by animal models. 25 A greater understanding of these mechanisms would be beneficial and provide opportunities to develop botulinum neurotoxins that reduce risk of spread.
CONCLUSION
The occurrence of significant negative health consequences after BoNT-A injections is not common, and for most children BoNT-A is an effective and safe intervention. Our study suggests that children with a history of dysphagia and/or aspiration pneumonia have the greatest likelihood of experiencing systemic adverse events after BoNT-A, and that these factors are more important than GMFCS level or BoNT-A dose. Further research is required to better understand the potential causative role of BoNT-A in adverse events.
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RESUMEN EVENTOS ADVERSOS SIST EMICOS DESPU ES DE INYECCIONES DE NEUROTOXINA A BOTUL INICA EN NIÑOS CON PAR ALISIS CEREBRAL
OBJETIVO Identificar los factores que aumentan la probabilidad de eventos sist emicos adversos despu es de las inyecciones de neurotoxina botul ınica tipo A (BoNT-A, siglas en ingles) en niños con par alisis cerebral (PC).
M ETODO Es un estudio observacional prospectivo de pacientes que asisten a la cl ınica de BoNT-A en un hospital pedi atrico terciario (2010-2014). Se demostr o la aparici on de eventos sist emicos adversos, como enfermedades del tracto respiratorio inferior, debilidad generalizada, disfagia y muerte en el seguimiento. Se examin o la relaci on entre estos eventos y ocho variables preinyecci on, entre ellas; edad, nivel del Sistema de Clasificaci on de la Funci on Motora Gruesa [GMFCS], antecedentes de disfagia, gastrostom ıa, neumon ıa por aspiraci on, antecedentes recientes de enfermedad, dosis de BoNT-A y tipo de sedaci on, realiz andose regresi on log ıstica univariable y multivariable con m etodos de ecuaciones de estimaci on generalizadas.
RESULTADOS En total, 591 niños se sometieron a 2,219 episodios de inyecci on con seguimiento en 2,158 (97%) casos. Se informaron eventos sist emicos adversos en 77 (3,6%) de los casos. El an alisis univariable sugiri o que los niveles IV y V de GMFCS, con historia de disfagia, gastrostom ıa, neumon ıa por aspiraci on y aumento de la dosis de BoNT-A, aumentan la probabilidad de que ocurran eventos sist emicos adversos. En el an alisis multivariable, aquellos con un historial de disfagia (odds ratio [OR] 3,42) y/o neumon ıa por aspiraci on (OR 2,31) permanecieron asociados a una mayor probabilidad de eventos sist emicos.
INTERPRETACI
ON Los antecedentes de disfagia y/o neumon ıa por aspiraci on son los factores que m as aumentan la probabilidad de eventos adversos sist emicos despu es de la BoNT-A. M ETODO Um estudo prospectivo observacional de pacientes que frequentam uma cl ınica de NTBo-A em um hospital pedi atrico terci ario (2010-2014). Ocorrências de eventos adversos sistêmicos, definidos como doenc ßas do trato respirat orio, fraqueza generalizada, disfagia, e obito foram determinadas no acompanhamento. As relac ßões entre efeitos adversos sistêmicos e oito vari aveis pr e-injec ßão (idade, n ıvel segundo o Sistema de Classificac ßão da Func ßão Motora Grossa [GMFCS], hist orico de disfagia, gastrostomia, pneumonia por aspirac ßão, hist orico recente de doenc ßa, dose de NTBo-A e tipo de sedac ßão) foram examinadas usando regressão log ıstica uni e multivariada com m etodos de equac ßões estimadas genaralizadas.
RESUMO EVENTOS ADVERSOS SISTÊMICOS AP OS INJEC ßÕES
RESULTADOS No total, 591 crianc ßas passaram por 2219 epis odios de injec ßões, acompanhamento de 2158 casos (97%). Efeitos adversos sistêmicos foram relatados em 77 (3,6%) epis odios de injec ßão. An alise univariada sugeriu que os n ıveis GMFCS IV e V, hist orico de disfagia, gastrostomia, pneumonia por aspirac ßão, e maior dose de NTBo-A aumentaram a probabidade de efeitos adversos sistêmicos. Na an alise multivariada, a hist oria de disfagia (odds ratio [OR] 3,42) e/ou pneumonia por aspirac ßão (OR 2,31) permaneceram associados com probabilidade aumentada de efeitos adversos sistêmicos.
INTERPRETAC ßÃO Um hist orico de disfagia e/ou pneumonia por aspirac ßão são os fatores que mais aumentam a probabilidade de efeitos adversos sistêmicos ap os NTBo-A .   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 
